Anticancer effect of docetaxel/hydroxypropyl-beta-cyclodextrin complex without histamine release
- 152 Downloads
In this study, the anticancer effect and improved safety for hypesensitivity reactions of docetaxel/hydroxypropyl-beta-cyclodextrin complex (DCX-CD) were investigated. The preparation of DCX-CD was confirmed by using differential scanning calorimetry, X-ray powder diffraction analysis, and scanning electron microscope. The anticancer activity was tested in human lung cancer A549 cell-transplanted mice and the hypersensitivity was tested in Beagle dogs after intravenous administration of DCX-CD, Taxotere, and their respective vehicles. In the hypersensitivity test, plasma histamine levels were determined using an ELISA method. Our results showed that DCX-CD was pharmacologically equivalent to Taxotere. Furthermore, DCX-CD did not cause the release of histamines or any significant symptoms associated with hypersensitivity. These results suggested that DCX-CD could be a promising alternative to Taxotere for cancer chemotherapy with reduced side effects.
KeywordsDocetaxel HP-β-CD Anticancer activity Hypersensitivity
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry (NRF-2014R1A1A1A05002840).
- 15.Kim, T.K., Kim, I.S., Yoo, H.H.: Determination of docetaxel in rat plasma and its application in the comparative pharmacokinetics of Taxotere and SID530, a novel docetaxel formulation with hydroxypropyl-β-cyclodextrin. Biomed. Chromatogr. 27, 306–310 (2013)Google Scholar
- 16.Kim, T.K., Yoo, H.H., Kim, E.J., Sa, J.H., Lee, B.Y., Park, J.H.: Comparative protein binding of taxotere and SID530, a new docetaxel formulation with hydroxypropyl-beta-cyclodextrin, in human plasma in vitro. Pharmazie 67, 789–791 (2012)Google Scholar